Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic … Read more
Market Cap & Net Worth: Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443)
Chongqing Genrix Biopharmaceutical Co. Ltd. A (SHG:688443) has a market capitalization of $1.33 Billion (CN¥9.79 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #11222 globally and #2612 in its home market, demonstrating a 4.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Genrix Biopharmaceutical Co. Ltd. A's stock price CN¥26.70 by its total outstanding shares 366680000 (366.68 Million).
Chongqing Genrix Biopharmaceutical Co. Ltd. A Market Cap History: 2023 to 2026
Chongqing Genrix Biopharmaceutical Co. Ltd. A's market capitalization history from 2023 to 2026. Data shows change from $2.00 Billion to $1.33 Billion (-8.49% CAGR).
Chongqing Genrix Biopharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Genrix Biopharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
41.66x
Chongqing Genrix Biopharmaceutical Co. Ltd. A's market cap is 41.66 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $2.00 Billion | $1.21 Million | -$801.32 Million | 1647.96x | N/A |
| 2024 | $1.25 Billion | $30.09 Million | -$797.27 Million | 41.66x | N/A |
Competitor Companies of 688443 by Market Capitalization
Companies near Chongqing Genrix Biopharmaceutical Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Chongqing Genrix Biopharmaceutical Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Chongqing Genrix Biopharmaceutical Co. Ltd. A Historical Marketcap From 2023 to 2026
Between 2023 and today, Chongqing Genrix Biopharmaceutical Co. Ltd. A's market cap moved from $2.00 Billion to $ 1.33 Billion, with a yearly change of -8.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.33 Billion | -1.98% |
| 2025 | CN¥1.36 Billion | +8.57% |
| 2024 | CN¥1.25 Billion | -37.20% |
| 2023 | CN¥2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Chongqing Genrix Biopharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.33 Billion USD |
| MoneyControl | $1.33 Billion USD |
| MarketWatch | $1.33 Billion USD |
| marketcap.company | $1.33 Billion USD |
| Reuters | $1.33 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.